Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting.

ABSTRACT:

Purpose

The aim of this analysis was to characterize the spectrum of inflammatory changes arising from brolucizumab use in routine clinical practice.

Design

Retrospective analysis of fluorescein angiography (FA), fundus photography (FP) and OCT images taken at the time of adverse event.

Subjects

Brolucizumab-treated patients with neovascular age-related macular degeneration with retinal vasculitis (RV) and/or retinal vascular occlusion (RO) reported to Novartis Patient Safety between February 2020 and January 2021.

Methods

Ocular images were reviewed by an external reading center using predefined grading lists for FA, FP, and OCT.

Main outcome measures

Classification of images, the most common imaging features of RV and/or RO by each imaging modality, an

SUBMITTER: Grewal DS 

PROVIDER: S-EPMC10587630 | biostudies-literature | 2024 Jan-Feb

REPOSITORIES: biostudies-literature